Opalia Pharma

Recordati acquires Tunisian pharmaceutical Opalia Pharma

Friday, July 26, 2013

International pharmaceutical group Recordati has acquired Opalia Pharma, a Tunisian pharmaceutical company. The transaction is valued at $48 million, paid in cash, and is subject to prior approval by Tunisian authorities. Opalia Pharma markets dermatology, gastrointestinal and respiratory therapeutic products in a cGMP certified facility specialized in liquid and semi-solid forms.

[Read More]